Sigma-Aldrich and Scripps Research Institute collaborate to commercialise new reagents

Access to new reagents will be accelerated by an agreement between Sigma-Aldrich and The Scripps Research Institute (TSRI) which will help to commercialise those created in six Scripps research labs. The main aim is to reduce the delay between the production of novel reagents and their availability to the general research community, by allowing Sigma-Aldrich to produce them under licence.

The agreement celebrates the first such arrangement between a research institution and a reagents company, but is not the first that TSRI has established. In 2012, it forged an agreement with Bristol-Myers Squibb in which novel synthetic intermediates will be assessed for biological activity against BMS targets.

Earlier in 2013, TSRI also announced a collaboration with Janssen Pharmaceuticals, Inc. to search for new treatments and vaccines for infectious diseases, concentrating initially on influenza.